Key facts
- This page summarizes Mark Bryan Aguillard's Form 4 filing for DermTech, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Sep 2023, 20:45.
Mark Bryan Aguillard - 20 Sep 2023 Form 4 Insider Report for DermTech, Inc.
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- N/A
- Reported as of
- 20 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Sep 2023, 20:45:56 UTC
- Prior SEC filing
- 22 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Miller, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark Bryan Aguillard filed Form 4 for DermTech, Inc. on 22 Sep 2023.
Change
- Previous filing in this sequence was filed on 22 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DMTK
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +90,000
- Change %
- Price
- $0.000000
- Shares after
- 90,000
- Date
- 20 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DMTK
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +90,000
- Change %
- Price
- $0.000000
- Shares after
- 90,000
- Date
- 20 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $1.69
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2022 Inducement Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, (i) twelve forty-eighths (12/48) of the restricted stock units shall vest on September 20, 2024 and (ii) the remaining the remaining thirty-six forty-eighths (36/48) shall vest in twelve (12) equal installments of three forty-eighths (3/48) on the twentieth day of each third month following September 20, 2024 until the final vesting date on September 20, 2027.
Footnote F2
Subject to the reporting person's continued service, (i) twelve forty-eighths (12/48) of the shares of issuer common stock exercisable pursuant to this option shall vest on September 20, 2024 and (ii) the remaining thirty-six forty-eighths (36/48) shall vest in a series of thirty-six (36) equal monthly installments of one forty-eighth (1/48) over the thirty-six (36) months thereafter until the final vesting date on September 20, 2027.